NFKB1 and neoplasm: It should be noted that we also found that sorafenib treatment did not significantly affect the expression of FN-EDA in CAFs, suggesting that FN-EDA could stably activate the NF-κB signaling pathway to promote tumor cell survival under sorafenib treatment (Fig. 2G; Fig. S2C).